Cargando…

Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging

Rationale: Optimal intratumor distribution of an anticancer drug is fundamental to reach an active concentration in neoplastic cells, ensuring the therapeutic effect. Determination of drug concentration in tumor homogenates by LC-MS/MS gives important information about this issue but the spatial inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morosi, Lavinia, Matteo, Cristina, Ceruti, Tommaso, Giordano, Silvia, Ponzo, Marianna, Frapolli, Roberta, Zucchetti, Massimo, Davoli, Enrico, D'Incalci, Maurizio, Ubezio, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085221/ https://www.ncbi.nlm.nih.gov/pubmed/32210725 http://dx.doi.org/10.7150/ijbs.41395

Ejemplares similares

Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging
por: Giordano, Silvia, et al.
Publicado: (2016)

A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging
por: Giordano, Silvia, et al.
Publicado: (2017)

Determination of Paclitaxel Distribution in Solid Tumors by Nano-Particle Assisted Laser Desorption Ionization Mass Spectrometry Imaging
por: Morosi, Lavinia, et al.
Publicado: (2013)

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models
por: Morosi, Lavinia, et al.
Publicado: (2021)

3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors
por: Giordano, S., et al.
Publicado: (2016)

Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Petrillo, Marco, et al.
Publicado: (2019)

Pseudo-resistance to anticancer drugs
por: Davoli, Enrico, et al.
Publicado: (2022)

New activities for the anti-tumor agent trabectedin: taking two birds with one stone
por: D'Incalci, Maurizio, et al.
Publicado: (2013)

Pharmacokinetic Characterization of the DDAH1 Inhibitors ZST316 and ZST152 in Mice Using a HPLC-MS/MS Method
por: Mangoni, Arduino A., et al.
Publicado: (2022)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
por: Lorusso, Domenica, et al.
Publicado: (2020)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

Inhibition of tumor‐associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti‐PD‐1 therapy
por: Belgiovine, Cristina, et al.
Publicado: (2021)

A methodological approach to correlate tumor heterogeneity with drug distribution profile in mass spectrometry imaging data
por: Prasad, Mridula, et al.
Publicado: (2020)

Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice
por: Digifico, Elisabeth, et al.
Publicado: (2020)

Development and Validation of a HPLC–MS/MS Method to Measure Nifuroxazide and Its Application in Healthy and Glioblastoma-Bearing Mice
por: Ceruti, Tommaso, et al.
Publicado: (2022)

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
por: Guy, Holly, et al.
Publicado: (2018)

IDN 5390: an oral taxane candidate for protracted treatment schedules
por: Pratesi, G, et al.
Publicado: (2003)

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
por: Wallace, Katrine, et al.
Publicado: (2019)

Bioreducible Hydrophobin-Stabilized Supraparticles for Selective Intracellular Release
por: Maiolo, Daniele, et al.
Publicado: (2017)

Niraparib for ovarian cancer
Publicado: (2021)

Mitozolomide activity on human cancer cells in vitro.
por: Erba, E., et al.
Publicado: (1986)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

Flow cytometric analysis of DNA content in human ovarian cancers.
por: Erba, E., et al.
Publicado: (1989)

Reduced Expression of the ROCK Inhibitor Rnd3 Is Associated with Increased Invasiveness and Metastatic Potential in Mesenchymal Tumor Cells
por: Belgiovine, Cristina, et al.
Publicado: (2010)

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2019)

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2020)

DNA Damage Response and Immune Defense
por: Nastasi, Claudia, et al.
Publicado: (2020)

Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer—Current Use and Future Opportunities
por: Paracchini, Lara, et al.
Publicado: (2021)

Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer
por: Ansaloni, L, et al.
Publicado: (2015)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
por: Galmarini, Carlos M., et al.
Publicado: (2014)

Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence
por: Giordano, Silvia, et al.
Publicado: (2020)

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
por: Nie, Jing, et al.
Publicado: (2023)

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
por: Canil, Giovanni, et al.
Publicado: (2023)

Is PDGFR an important target for E-3810?
por: Damia, Giovanna, et al.
Publicado: (2012)

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer
por: Lorusso, Domenica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_15fa47s4a77pr29c4e1l4tcc6g